In last trading session, Perspective Therapeutics Inc (AMEX:CATX) saw 1.57 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price level of $2.05 trading at $0.09 or 4.59% at ring of the bell on the day assigns it a market valuation of $151.80M. That closing price of CATX’s stock is at a discount of -829.27% from its 52-week high price of $19.05 and is indicating a premium of 7.32% from its 52-week low price of $1.90. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.76 million shares which gives us an average trading volume of 773.87K if we extend that period to 3-months.
For Perspective Therapeutics Inc (CATX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.27 in the current quarter.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Upright in the green during last session for gaining 4.59%, in the last five days CATX remained trading in the red while hitting it’s week-highest on Thursday, 03/27/25 when the stock touched $2.05 price level, adding 14.94% to its value on the day. Perspective Therapeutics Inc’s shares saw a change of -35.74% in year-to-date performance and have moved -9.69% in past 5-day. Perspective Therapeutics Inc (AMEX:CATX) showed a performance of -12.77% in past 30-days. Number of shares sold short was 5.94 million shares which calculate 10.36 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 21 to the stock, which implies a rise of 90.24% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -875.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of -875.61% for stock’s current value.
Perspective Therapeutics Inc (CATX) estimates and forecasts
This year revenue growth is estimated to fall -58.25% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 136.17k for the same. And 8 analysts are in estimates of company making revenue of 110.21k in the next quarter. Company posted 325k and 526k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.86% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -5.33% while estimates for its earnings growth in next 5 years are of -9.76%.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Insiders are in possession of 18.63% of company’s total shares while institution are holding 64.38 percent of that, with stock having share float percentage of 79.12%. Investors also watch the number of corporate investors in a company very closely, which is 64.38% institutions for Perspective Therapeutics Inc that are currently holding shares of the company.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.69 shares of worth $3.47 million or 2.29% of the total outstanding shares. The later fund manager was in possession of 1.64 shares on Feb 28, 2025 , making its stake of worth around $3.37 million in the company or a holder of 2.22% of company’s stock.
